INCB-106385

N/A

Report date: 2024/11/07 13:42:09
NME

Base Information

Drug NameINCB-106385
Drug Alias NameINCB-106385
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonistsAdenosine A2b receptor antagonists
TargetsAdenosine A2a receptorAdenosine A2b receptor
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-Resistant +[11] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIncyte Corp
China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsProstatic Neoplasms, Castration-ResistantCarcinoma, Non-Small-Cell Lung +[9] 
Inactive IndicationsSolid tumoursGastrointestinal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A